Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.60 |
| ▸ | CDK8 | P49336 | 2/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662229 | 1.00 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL17545240 | 0.93 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL378881 | 0.90 | CDK8 (0.63) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3173937 | 0.90 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3179874 | 0.90 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3190583 | 0.87 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL16410082 | 0.86 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL2452394 | 0.86 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3179284 | 0.86 | CDK8 (0.52) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL2361698 | 0.86 | JAK2 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004097-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2018-01-17 | — | — | EP | disclosed |
| EP-3004097-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2018-01-17 | — | — | EP | disclosed |
| US-9440974-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| US-9440974-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| US-9440974-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| EP-3004097-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-20160016953-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2016-01-21 | — | — | US | disclosed |
| US-20160016953-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2016-01-21 | — | — | US | disclosed |
| US-20160016953-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2016-01-21 | — | — | US | disclosed |
| US-9181242-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181242-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181242-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-20140364412-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| US-20140364412-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| US-20140364412-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| WO-2014195402-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014195402-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016953-A1 | KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K6 | MAPK14 33/4885MAPK13 40/4885MAPK12 38/4885 |
| US-20140364412-A1 | KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K6 | MAPK14 33/4885MAPK13 40/4885MAPK12 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.